Q-omics provides the consensus-scored STT3B profile across patient tissues and cancer cell-line models. STT3B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, STT3B is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, STT3B protein abundance shows 24,331 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight COAD, BLCA, and GBM as cancer lineages where STT3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STT3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STT3B survival associations across molecular data types. STT3B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STT3B RNA expression–survival associations across cancer types. High STT3B expression shows unfavorable associations in PAAD, LGG, CESC and LIHC, but favorable associations in COAD and KIRC. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for STT3B RNA expression.
This table summarizes STT3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for STT3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STT3B shows lower tumor expression in THCA and higher tumor expression in BLCA, LIHC, BRCA, COAD and STAD. The BLCA box plot shows higher STT3B RNA expression in tumor versus normal tissue (log2 FC = +0.790, t-test p < 0.001).
This table shows molecular features associated with STT3B in patient tissues and cancer cell lines. In patient samples, STT3B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, STT3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
